Colorectal Cancer

Drug company receives U.S. FDA approval for new Eloxatin formulation

Published in Genomics and Genetics Weekly, March 11th, 2005

The sanofi-aventis Group announced that it has received marketing approval from the United States Food and Drug Administration (FDA) for a new aqueous solution formulation of Eloxatin (oxaliplatin injection).

This new formulation, Eloxatin (oxaliplatin injection) injection, is a clear, preservative-free, colorless solution, which does not require reconstitution prior to dilution and administration.

Eloxatin injection offers additional convenience to physicians and nurses since it involves fewer steps in the administration of Eloxatin.

Eloxatin received approval in France for the second-line treatment of metastatic colorectal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly

Source: Genomics and Genetics Weekly (2005-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry